ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Targeted therapy for uncontrolled erythrocytosis in PV with rusfertide
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 257234" data-attributes="member: 13851"><p>[MEDIA=youtube]YPkMU6CTlXY[/MEDIA]</p><p></p><p><em>Elevated hematocrit is a hallmark of polycythemia vera (PV), and it is associated with higher rates of death. Whilst it is essential to maintain hematocrit levels below 45% to decrease the risk of thrombotic and cardiovascular events, current standards of care (SOC) are not effective in the majority of patients. In this presentation, Ronald Hoffman, MD, presents results from the REVIVE study (NCT04057040), which evaluated the efficacy of rusfertide, a novel hepcidin mimetic, in patients with PV. The study met its primary endpoint of maintaining hematocrit levels below 45% and demonstrated that rusfertide was highly efficacious in controlling erythrocytosis. The data from the randomized withdrawal phase demonstrated the superior efficacy of rusfertide in eliminating the need for additional therapeutic phlebotomies as compared to placebo. Rusfertide therapy was associated with persistent hematocrit (HCT) control and improvements in PV-related symptoms. The treatment was generally well tolerated. The positive outcomes of the REVIVE study showcase the efficacy and tolerability of rusfertide as a highly effective therapy for uncontrolled erythrocytosis and associated symptoms in PV and is currently being investigated in the ongoing Phase III VERIFY study (NCT05210790). This press briefing took place at the European Hematology Association (EHA) Congress 2023, held in Frankfurt, Germany.</em></p></blockquote><p></p>
[QUOTE="madman, post: 257234, member: 13851"] [MEDIA=youtube]YPkMU6CTlXY[/MEDIA] [I]Elevated hematocrit is a hallmark of polycythemia vera (PV), and it is associated with higher rates of death. Whilst it is essential to maintain hematocrit levels below 45% to decrease the risk of thrombotic and cardiovascular events, current standards of care (SOC) are not effective in the majority of patients. In this presentation, Ronald Hoffman, MD, presents results from the REVIVE study (NCT04057040), which evaluated the efficacy of rusfertide, a novel hepcidin mimetic, in patients with PV. The study met its primary endpoint of maintaining hematocrit levels below 45% and demonstrated that rusfertide was highly efficacious in controlling erythrocytosis. The data from the randomized withdrawal phase demonstrated the superior efficacy of rusfertide in eliminating the need for additional therapeutic phlebotomies as compared to placebo. Rusfertide therapy was associated with persistent hematocrit (HCT) control and improvements in PV-related symptoms. The treatment was generally well tolerated. The positive outcomes of the REVIVE study showcase the efficacy and tolerability of rusfertide as a highly effective therapy for uncontrolled erythrocytosis and associated symptoms in PV and is currently being investigated in the ongoing Phase III VERIFY study (NCT05210790). This press briefing took place at the European Hematology Association (EHA) Congress 2023, held in Frankfurt, Germany.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Targeted therapy for uncontrolled erythrocytosis in PV with rusfertide
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top